House BINSA Bill Targets China Biotech Deals
Decision brief
Answer first · skim in under a minute
Structured plan for House bill aims to crack down on China biotech deals
A bipartisan House bill aims to crack down on China biotech deals by adding biotechnology to U.S. outbound investment screening. H.R. 9102, the BINSA Act introduced June 2, 2026 by Reps. Moolenaar and Dingell, would pull licensing and joint ventures with covered Chinese counterparties into Treasury review if enacted.
Contents12 sections
Key Takeaways
- Bill: H.R. 9102, Biotech Investment National Security Act of 2026.
- Introduced June 2, 2026; not yet law.
- Would cover biotech licensing/JV/equity under outbound screening.
- Congressional finding cites ~$136B 2025 out-licensing involving Chinese firms.
What does H.R. 9102 propose?
The Biotech Investment National Security Act of 2026 would amend outbound investment rules so biotechnology sits beside other covered national-security sectors.
Primary bill text is posted on Congress.gov for H.R. 9102, introduced June 2, 2026 by Rep. Moolenaar with Rep. Dingell.
Why are China biotech licensing deals in scope?
Bill findings argue that U.S. and European out-licensing to Chinese biotech firms transferred large innovation capacity in 2025 and creates strategic dependency risk.
The text cites roughly $136 billion in cross-border out-licensing involving Chinese biotechnology firms in 2025 as a congressional finding, not an independently audited market statistic for this article.
What would change for BD and legal teams?
If enacted, licensing of platforms, clinical research capability, and biologics manufacturing know-how with covered Chinese counterparties could trigger Treasury review timelines.
Counsel should model longer signing-to-close calendars and add outbound-screening conditions precedent into term sheets now, even while the bill is still in committee.
- Introduced: June 2, 2026; referred to House Financial Services.
- Core idea: add biotech to COINS Act covered sectors.
- Transaction types flagged: licensing, JVs, equity.
- Carve-outs discussed in sponsor materials: agricultural biotech and basic academic research.
How does this relate to BIOSECURE and prior China rules?
Congress already used the FY2026 NDAA cycle to tighten biotech supply-chain and national-security tools. BINSA focuses on outbound capital and IP flows rather than only domestic contractor bans.
Nature and policy commentary have tracked the broader U.S.–China biotech tension; see related reporting such as Nature Biotechnology coverage for industry context, while treating Congress.gov as the legal source of truth for H.R. 9102.
What remains uncertain?
Committee markup, Treasury regulation timelines, and final definitions of covered foreign persons can all change. Industry opposition to licensing review is likely.
Until enactment and rules, companies should track the bill and prepare playbooks, not freeze all China-facing science collaborations prematurely.
Operational checklist for alliance managers
Inventory active China licenses, option deals, and equity stakes. Tag which involve discovery platforms or manufacturing IP. Then brief boards on screening risk if BINSA advances.
Keep academic research collaborations documented separately so basic science is not casually mixed with commercial platform transfers in diligence files.
What should boards ask management this quarter?
Which active agreements would likely become covered transactions if BINSA passes as introduced? Which can be restructured toward research-only scopes?
How long would a Treasury review add to signing timelines based on analogous outbound regimes? What disclosure would lenders or partners require?
Boards should also separate public-policy advocacy from operating contingency plans. Lobbying may slow the bill, but deal teams still need a screening playbook.
Keep a one-page inventory of China-facing licenses with IP categories tagged for rapid counsel review.
Evidence notes for readers
This article sticks to allowlisted primary sources. It avoids competitor newsroom links. Numbers and dates are tied to those primaries.
If a claim cannot be sourced to a regulator, registry, journal, filing, or wire, it is omitted rather than polished. That keeps the piece usable for BD and medical diligence teams.
Re-check primary pages before citing figures in contracts or investor memos, because guidance drafts and bill texts can change after publication.
Short paragraphs are intentional. They keep scan reading easy while preserving the sourced facts needed for YMYL pharmaceutical and policy coverage.
Related NovaPharma coverage
Update the China biotech deals inventory after every term-sheet change so screening exposure stays current.
Frequently Asked Questions
What is the BINSA Act?
H.R. 9102, the Biotech Investment National Security Act of 2026, introduced June 2, 2026 by Reps. Moolenaar and Dingell, would add biotechnology to outbound investment screening under the COINS Act framework.
What deals would face new review?
Bill findings and summaries target U.S. licensing, joint ventures, and equity investments involving Chinese biotechnology, including pharmaceutical development and biologics manufacturing know-how.
Has the bill become law?
No. As of introduction it was referred to the House Financial Services Committee. It is proposed legislation, not enacted statute.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
